
    
      The objective of this study is to provide adefovir dipivoxil 10 mg once daily to patients
      with chronic hepatitis B virus(HBV) infection who have completed a Gilead-sponsored study of
      adefovir dipivoxil and require continued access to adefovir dipivoxil. The secondary
      objective of this study is to evaluate the safety of chronic therapy with adefovir dipivoxil
      10 mg.
    
  